Neuromuscular Manifestations and Hyperparathyroidism
Primary Neuromuscular Manifestations
Hyperparathyroidism causes reversible neuromuscular dysfunction that includes muscle weakness, fatigue, reduced muscle thickness, and impaired lower extremity function, with improvement occurring after parathyroidectomy, particularly when serum calcium is reduced. 1
The neuromuscular manifestations of hyperparathyroidism have evolved significantly in their clinical presentation:
Classic vs. Modern Presentations
In contemporary practice, the severe neuromuscular syndrome historically associated with hyperparathyroidism is rarely observed 2. Modern patients typically present with:
- Muscle weakness and easy fatigability (most common subjective complaints)
- Paresthesias and muscle cramps (reported in 52% of patients) 2
- Reduced handgrip strength
- Prolonged timed-up-and-go and five-time sit-to-stand test durations
- Decreased gastrocnemius muscle thickness 1
- Impaired lower limb functional performance 1
Severe Manifestations (Rare in Modern Practice)
In elderly patients or those with severe hypercalcemia, more dramatic presentations can occur:
- Paraparesis with areflexia and unsteady gait
- Episodes of slurred speech and diplopia
- Altered mental status ranging to coma 3
- Stocking-glove loss of pain sensation or diminished vibratory sensation 2
A critical pitfall: severe hypercalcemia from hyperparathyroidism can simulate acute polyneuritis 3. Always obtain urgent serum calcium as part of a bone profile in patients presenting with acute neurological symptoms, especially in the elderly.
Management Approach
Surgical Management (Definitive Treatment)
Parathyroidectomy is the only curative treatment and should be offered to patients meeting surgical criteria 4. Surgery is indicated when one or more of the following conditions are present:
- Bone involvement: T-score <-2.5 SD on densitometry or low-energy fracture
- Renal complications: proven renal stones, nephrocalcinosis, or eGFR <60 mL/min/1.73 m²
- Severe hypercalcemia: blood calcium >0.25 mmol/L (10 mg/L) above upper normal limit
- Hypercalciuria: >6.25 mmol/day (250 mg/day) in women or >7.5 mmol/day (300 mg/day) in men 4
Neuromuscular Recovery After Surgery
Following parathyroidectomy, both gastrocnemius muscle thickness and lower limb functional performance improve significantly within 3 months 1. The evidence demonstrates:
- 15 of 17 patients (88%) with muscle weakness reported significant improvement 5
- 14 of 15 patients (93%) with fatigue and lethargy improved 5
- Reduction in serum calcium is the independent predictor of functional improvement, not PTH decline 1
This finding is clinically important: the calcium reduction itself drives neuromuscular recovery, suggesting that achieving normocalcemia is the therapeutic target.
Medical Management (Non-Surgical Candidates)
For patients who cannot undergo surgery or do not meet surgical criteria 4:
- Calcium intake: Follow general population recommendations (800-1000 mg/day based on age and sex)
- Vitamin D supplementation: Target 25(OH)D >30 ng/mL
- Cinacalcet: Consider if calcium is >0.25 mmol/L above upper normal limit
- Bisphosphonates (alendronate) or denosumab: If osteoporosis is present
Important caveat: Medical treatment has never been shown to improve cognitive ability, quality of life, or neuromuscular symptoms in hyperparathyroidism patients 6. These therapies address biochemical abnormalities and bone density but do not reverse neuromuscular dysfunction.
Regarding Neurobehavioral Symptoms
The 2025 French consensus acknowledges that neurobehavioral manifestations (fatigue, mood swings, depression, memory disorder, irritability, physical weakness, difficulty rising from a chair) may improve with surgery 6. However, surgery cannot be recommended based solely on these symptoms without meeting other validated surgical criteria 6. If cardiovascular or neurobehavioral manifestations are present alongside validated surgical criteria, proceed with surgery; otherwise, discuss in a multidisciplinary setting.
Monitoring Non-Surgical Patients
Patients not undergoing surgery require annual evaluation for disease progression 7, watching for development of surgical indications.